Physician profile
Narayan Michael Saha
NPI 1396033825
$2,569.99
in general payments reported to CMS, 2019-2025
19 companies · $272 in 2025
The $272 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $171 · 2021: $200 · 2022: $387 · 2023: $239 · 2024: $325 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,187.45 | 2019-2025 | |
| Pfizer INC. | $212.67 | 2019-2024 | |
| Abbott Laboratories | $172.03 | 2022-2024 | Cardiomems |
| Amgen INC. | $145.75 | 2019-2024 | Repatha |
| Edwards Lifesciences Corporation | $135.65 | 2019-2020 | |
| Heartflow, INC. | $130.76 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $106.94 | 2019-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.20 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $74.84 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.34 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $50.95 | 2019 | |
| Amarin Pharma, INC. | $36.80 | 2019 | |
| Bridgebio Pharma, INC. | $36.01 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $27.44 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $20.43 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $20.32 | 2019 | |
| Lundbeck LLC | $19.88 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.39 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $13.14 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narayan Saha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.